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Abstract
Objective—To determine if change in maternal angiogenic biomarkers between the first and
second trimesters predicts pre-eclampsia in low-risk nulliparous women.
Design—A nested case–control study of change in maternal plasma soluble Flt-1 (sFlt-1), soluble
endoglin (sEng) and placenta growth factor (PlGF). We studied 158 pregnancies complicated by
pre-eclampsia and 468 normotensive nonproteinuric controls.
Setting—A multicentre study in 16 academic medical centres in the USA.
Population—Low-risk nulliparous women.
Methods—Luminex assays for PlGF, sFlt-1 and sEng performed on maternal EDTA plasma
collected at 9–12, 15–18 and 23–26 weeks of gestation. Rate of change of analyte between first
and either early or late second trimester was calculated with and without adjustment for baseline
clinical characteristics.
Main outcome measures—Change in PlGF, sFlt-1 and sEng.
Results—Rates of change of PlGF, sEng and sFlt-1 between first and either early or late second
trimesters were significantly different in women who developed pre-eclampsia, severe pre-
eclampsia or early-onset pre-eclampsia compared with women who remained normotensive.
Inclusion of clinical characteristics (race, body mass index and blood pressure at entry) increased
sensitivity for detecting severe and particularly early-onset pre-eclampsia but not pre-eclampsia
overall. Receiver operating characteristics curves for change from first to early second trimester in
sEng, PlGF and sFlt-1 with clinical characteristics had areas under the curve of 0.88, 0.84 and
0.86, respectively, and for early-onset pre-eclampsia with sensitivities of 88% (95% CI 64–99%),
77% (95% CI 50–93%) and 77% (95%CI 50–93%) for 80% specificity, respectively. Similar
results were seen in the change from first to late second trimester.
Conclusion—Change in angiogenic biomarkers between first and early second trimester
combined with clinical characteristics has strong utility for predicting early-onset pre-eclampsia.
Keywords
Angiogenesis; endoglin; platelet growth factor; pre-eclampsia; sFlt-1
Introduction
Pre-eclampsia, a leading cause of fetal growth restriction, indicated premature delivery and
maternal death, affects up to 7% of pregnancies in the USA and is responsible for over 50
000 maternal deaths annually worldwide.1,2 There is currently major interest in developing
biomarkers to predict, early in gestation, those women who will develop pre-eclampsia,
particularly early-onset or severe pre-eclampsia.
Myatt et al. Page 2






















Pre-eclampsia is described as a two-stage phenomenon with abnormal placentation or
uteroplacental perfusion leading to increased inflammatory response and endothelial
dysfunction giving the systemic maternal syndrome.3 Proposed biomarkers for predicting
onset or severity have been those that measure trophoblast invasion, impedance to
uteroplacental blood flow, placental function, or production of pro-angiogenic and anti-
angiogenic factors. In cross-sectional studies of women with established pre-eclampsia,
clear differences have been seen in levels of pro-angiogenic and anti-angiogenic
biomarkers.4,5 Although a high degree of sensitivity and specificity for prediction of pre-
eclampsia is claimed for first-trimester measurement of biomarkers,6–8 our study in a low-
risk nulliparous population9 and a recent systematic review of 37 studies assessing 71
different combinations of biochemical and ultrasonographic markers10 suggest that current
first-trimester biomarkers may not have sufficient sensitivity to be clinically useful. Cross-
sectional studies of biomarkers in late gestation show more distinct differences between
normotensive women and those who will develop pre-eclampsia. Therefore, measuring
changes in biomarkers between the first and second trimesters has been proposed as a better
early predictor than single first-trimester values.11
The study objective was to test the hypothesis that measurement of change in angiogenic
biomarker levels between the first and early or late second trimesters has clinical utility in
predicting pre-eclampsia. Although pre-eclampsia occurs at a higher rate in women with
pre-existing risk factors,12 this study used low-risk nulliparous women.
Methods
Study design
The Maternal Fetal Medicine Units network of the Eunice Kennedy Shriver National
Institute of Child Health and Human Development conducted this study as a planned
observational cohort of a larger randomised controlled trial to determine whether antioxidant
supplementation (1000 mg vitamin C and 400 IU vitamin E) prevents pre-eclampsia in
nulliparous women at low risk for developing the syndrome. Full details of the trial have
been reported previously.13 Women were eligible to participate in this cohort if they were
enrolled in the trial and their gestational age at enrolment was between 9 weeks 0 days and
12 weeks 6 days. Exclusion criteria were: a previous pregnancy lasting beyond 19 weeks 6
days, an elevated blood pressure (systolic pressure ≥ 135 mmHg or diastolic blood pressure
≥ 85 mmHg), proteinuria (24-hour urine collection of ≥ 300 mg protein or a dipstick value
more than trace), current use of antihypertensive medication, pre-gestational diabetes,
regular use or use within 7 days of platelet active drugs or nonsteroidal anti-inflammatory
agents, known fetal abnormalities or demise, and a history of medical complications.
Clinical information including demographic, medical, obstetric, social and sexual history
was obtained at the time of enrolment by patient interview and chart review. Blood pressure,
weight and urine protein concentrations were recorded at monthly study visits. Blood was
collected into EDTA tubes at 9–12, 15–18 and 23–26 weeks of gestation, plasma separated,
divided into aliquots and stored at – 70°C until analysis. A nested case–control study was
performed with approximately a 3 : 1 random sample of normotensive, nonproteinuric
women to women with pre-eclampsia, matched by centre and gestational age at enrolment.
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We measured platelet growth factor (PlGF), a vascular endothelial gowth factor (VEGF)
family member involved in angiogenesis, sFlt, the soluble form of Flt-1 VEGF receptor, and
soluble endoglin (sEng), a transforming growth factor-β co-receptor in EDTA plasma.
Details of their assay have been reported previously.9 The biomarkers were measured using
Luminex assays developed by Rules Based Medicine (Austin, TX, USA). The inter-assay
coefficients of variation were 9% at 1.378 ng/ml for sFlt-1, 8% at 3.91 ng/ml for sEng, and
10% at 476 pg/ml for PlGF.
Definitions and outcomes
The primary outcome was the development of pre-eclampsia. Secondary outcomes included
the severity and gestational age of pre-eclampsia onset. Mild pre-eclampsia was defined as
mild pregnancy-associated hypertension (140–159 mmHg systolic or 90–109 mmHg
diastolic on two occasions, 2–240 hours apart) and proteinuria (300–4999 mg total
protein/24 hours, 2 + or higher on dipstick testing, or a protein : creatinine ratio of ≥ 0.35).
Severe pre-eclampsia was defined as pre-eclampsia with either severe pregnancy-associated
hypertension (≥ 160 mmHg systolic or ≥ 110 mmHg diastolic on two occasions, 2–240
hours apart, or a single occurrence treated with anti-hypertensives) or protein excretion of 5
g or more in a 24-hour urine sample or as mild pregnancy-associated hypertension with
oliguria (< 500 ml), pulmonary oedema, or thrombocytopenia (platelet count of < 100
000/mm3). Pre-eclampsia included mild and severe pre-eclampsia, HELLP (haemolysis,
elevated liver enzymes, low platelet count) syndrome and eclampsia. The time of onset of
pre-eclampsia (early onset defined as ≤ 34 weeks or late onset defined as ≥ 34 weeks of
gestation) was determined as the time at which individuals first met the criteria for diagnosis
of pre-eclampsia given above.
Pre-eclampsia was confirmed via central review, using a standardised protocol by three
reviewers not associated with the clinical site of origin, of de-identified medical records of
all women with pregnancy-associated hypertension.9
Statistical analysis
Categorical variables were compared using the chi-square test and continuous variables
using the Wilcoxon rank sum test. The change in biomarker concentrations between the first
(9–12 weeks) and early second (15–18 weeks of gestation) trimesters and between first and
late second (23–26 weeks of gestation) trimesters was calculated as rate of change =
difference in concentration (pg/ml or ng/ml) divided by number of weeks between
measurements. The performance of screening was determined with and without adjustment
for significant clinical factors by receiver operating characteristic curves and calculating the
sensitivity for a fixed 80% specificity.
Unless specifically noted, a nominal P value less than 0.05 indicated statistical significance
and no adjustments were made for multiple comparisons. Analyses were performed using
SAS software (SAS Inc., Cary, NC, USA).
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A total of 626 women, 158 diagnosed with pre-eclampsia and 468 normotensive, non-
proteinuric, had biomarkers available in both the first trimester and early second trimester.
Of these, five delivered before 23 weeks of gestation and 109 did not have a late second
trimester blood collection, such that 137 women with pre-eclampsia and 375 normotensive
control women were available and used in comparisons of first and late second trimester
values. The population characteristics for all women included in the analysis are reported in
Table 1. The median gestational age at enrolment was 11.4 weeks (pre-eclampsia) and 11.6
weeks (normotensive controls). Overall there was a significant difference in ethnicity
between the women who developed pre-eclampsia and those who remained normotensive.
Although there was no difference in the proportion of women who were Hispanic between
groups, more women were African American in the pre-eclampsia group with a
corresponding reduction in the proportion who were Caucasian. Of those women in this
analysis, 13.6% had a family history of pre-eclampsia, 16.8% were smokers and 20.9% had
been previously pregnant; there was no difference in these incidences between those who
developed pre-eclampsia and those who remained normotensive. However, median body
mass index (BMI) and systolic and diastolic blood pressures were significantly greater at
enrolment in those women who subsequently developed pre-eclampsia. Patients were
equally randomised to vitamins or antioxidants in the clinical trial. The overall incidence of
pre-eclampsia among women in this trial was 7.6% and was not different between those who
did or did not receive antioxidants.
Angiogenic markers
There was no effect of supplementation with vitamins on the concentrations of angiogenic
factors. In women who remained normotensive maternal concentrations of both sFlt-1 and
PlGF increased from first to early second trimester and from first to to late second trimester
(as evidenced by the rate of change, Tables 2 and 3) whereas the concentration of sEng
declined slightly over this time. The rates of the change in the biomarkers between first and
early second trimesters were significantly different for sEng and PlGF, but not for sFlt-1,
between those individuals who developed pre-eclampsia and those who remained
normotensive (Table 2). When the different clinical phenotypes of pre-eclampsia were
considered the rates of change in sEng and PlGF were again significantly less in those who
developed severe pre-eclampsia compared with those who remained normotensive (Table 2).
However, only the rate of change for sEng between first and early second trimesters barely
reached significance and that for sFlt and PlGF was not significantly different for those who
developed early onset pre-eclampsia compared with women who remained normotensive
(Table 2). When receiver operating characteristic curves were constructed for the change in
biomarkers, the greatest areas under the curve (AUC) were for sEng (0.61, 95% CI 0.54–
0.68) and for PlGF (0.62, 95% CI 0.54–0.70) for those women who developed severe pre-
eclampsia (Figure 1A) and 0.64 (95% CI 0.49–0.79) and 0.60 (95% CI 0.43–0.77),
respectively, for those who developed early onset pre-eclampsia (Figure 1B). The sensitivity
of PlGF for predicting early onset pre-eclampsia was 47% (95% CI 23–72%) at an 80%
specificity but only 41% (95% CI 29–54%) for prediction of severe pre-eclampsia. When
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data for change between first trimester and late second trimester were considered, the rate of
change for PlGF (reduced), sFlt-1 but not sEng was significantly different in women who
developed pre-eclampsia compared with women who remained normotensive (Table 3).
The rate of change for all three analytes was significantly different in women who
developed severe pre-eclampsia compared with women who remained normotensive. Only
the rate of change of PlGF was significantly different comparing those who developed early
onset pre-eclampsia with those who remained normotensive (Table 3). The predictive
performance was reanalysed following addition of the clinical characteristics, race, BMI and
blood pressure at enrolment. For changes from first to early second trimester (Table 4) each
analyte still only yielded an AUC < 0.70 and a sensitivity < 45% at 80% specificity for
predicting pre-eclampsia (Figure 1C,D, Table 4). However, for prediction of early onset pre-
eclampsia the AUC for sEng was 0.88 (95% CI 0.83–0.93) yielding a sensitivity of 88.2%
(95% CI 63.6–98.5%) at 80% specificity, with performance of sFlt-1 and PlGF only slightly
less (Figure 1E, Table 4). The performance for predicting severe pre-eclampsia (Figure 1F,
Table 4) was better than that of the biomarkers alone (Figure 1B) but did not match that for
prediction of early-onset pre-eclampsia. Similar results were seen for the change from first
to late second trimester (Table 5). The sensitivity of PlGF for severe pre-eclampsia reached
60% and the sensitivity of sFlt for prediction of early onset pre-eclampsia now reached 80%.
Discussion
In this study examining rates of change in pro-angiogenic and anti-angiogenic markers alone
from the late first to early second trimester in the low-risk nulliparous population, we find
no better sensitivity for predicting pre-eclampsia than our previous analysis of first-trimester
markers alone, as ratios or in combination with clinical indices (AUC 0.73 and sensitivity
46% at 20% false-positive rate).9 However, the combination of change in biomarkers with
the baseline clinical characteristics of race, BMI and blood pressure increased predictive
performance. Performance for pre-eclampsia and severe pre-eclampsia still only reached the
levels reported previously using first-trimester biochemical and clinical indices,9 an AUC of
0.88 and sensitivity of 88% for early-onset pre-eclampsia was achieved for change in
soluble endoglin between first trimester (median 11 weeks) and early second trimester (15–
18 weeks). Measuring change between first and late second trimester with clinical
characteristics yielded a slightly lower AUC and sensitivity for detecting early-onset pre-
eclampsia with sEng but the performance of all three angiogenic factors for detection of
severe pre-eclampsia improved somewhat with PlGF giving an AUC of 0.74 and sensitivity
of 59%.
This study is unique as a prospectively designed longitudinal study in a population at low
risk for developing pre-eclampsia enrolled in the first trimester. All material was collected
and biophysical measurements were performed in a standardised manner by personnel
trained in the methodology. Pre-eclampsia was defined according to pre-established criteria
and independently reviewed by a panel of three individuals blinded to patient identity. The
women were part of a randomised trial of antioxidants.13 We focused on nulliparous women
because this group accounts for most cases of pre-eclampsia in clinical practice. We
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performed by far the largest, comprehensive longitudinal study of trophoblast and
angiogenic markers.
Placental growth factor shares homology with VEGF, which can induce proliferation,
migration and activation of endothelial cells,14 but which is expressed in villous
cytotrophoblast, syncytiotrophoblast and extravillous trophoblast.15,16 Women who
subsequently develop pre-eclampsia show reduced PlGF concentrations even in the first
trimester and the difference between these women and those who remain normotensive
becomes more marked as pregnancy progresses.17 Of the angiogenic factors we have
measured in the first trimester, PlGF has the best predictive power but has a low sensitivity.9
Maternal blood concentrations of the anti-angiogenic factors sFlt-1 and sEng, both also
produced by trophoblast,18 are low throughout the first and second trimesters and only
increase markedly in the third trimester. Previously Vatten et al.19 using a retrospective
nested case–control study of women of all parities and Kusanovic et al.20 using a
longitudinal cohort approach performed similar studies for PlGF, VEGF, sFlt-1 and sEng
reporting that change in concentration of PlGF from first to either early or late second
trimester was the best predictor, being significantly different both for all pre-eclampsia and
for any of the four clinical phenoytypes, mild, severe, early onset or late onset from women
who remained normotensive. We find that the rate of change of PlGF was significantly
different for all three phenotypes examined, except for early-onset pre-eclampsia, using data
from first to early second trimester. The small number (n = 17) of women with early onset
(< 34 weeks of gestation) potentially limited the predictive power of our analysis for this
subtype, although we have more cases than Kusanovic et al.20 at < 34 weeks (n = 9) and
Vatten et al.19 only studied < 37 weeks of gestation. In contrast to PlGF, the rate of change
from first to early second trimester for sEng was significantly different for all pre-eclampsia,
severe pre-eclampsia and early-onset pre-eclampsia, but that for sFlt-1 was not related to
any subtype. When examining change from first to late second trimester, sEng is only
significant for severe pre-eclampsia and sFlt-1 for all pre-eclampsia and severe pre-
eclampsia. The sensitivity of such change for severe pre-eclampsia reached 60% for PlGF
from first to late second trimester at a fixed 80% specificity. For early-onset pre-eclampsia
the sensitivity was better, reaching 73–77% for early and late second time intervals. Earlier
studies had also shown that a combination of the slopes of PlGF and sEng gave the best
predictive value particularly for early-onset pre-eclampsia.19,20 Indeed the study by
Kusanovic et al.20 claimed a sensitivity of 100% with a specificity of 98–99% for prediction
of early-onset pre-eclampsia using the PlGF : sEng ratio. Determining the slopes of the
PlGF : sFlt or PlGF : sEng ratios did not improve sensitivity above that of PlGF alone (data
not shown).
Conclusion
In contrast to previous reports we do not find that assessment of changes in angiogenic
markers alone from first to second trimester can improve predictive power. However,
addition of baseline clinical characteristics improved the predictive power for severe and
particularly for early-onset pre-eclampsia such that sensitivity reached 88% at an 80%
specificity. This differential sensitivity for detection of early-onset pre-eclampsia reinforces
the idea that the there may be more than one pathophysiological phenotype.21 As the utility
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of therapeutic intervention to change the pathological course or of surveillance would be
enhanced by prediction as early as possible in gestation, measurement of change between
first trimester (median 11 weeks) and early second trimester (15–18 weeks) appears to have
the most value, particularly as the test has highest sensitivity for early-onset pre-eclampsia,
the group with shortest time available for intervention. Future studies should focus on the
utility of combinations of biomarkers and clinical factors in prediction of different clinical
phenotypes of pre-eclampsia.
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Receiver operating characteristic curves for rate of change in concentration of biomarkers
between first and early second trimester for (A) early-onset pre-eclampsia and (B) severe
pre-eclampsia, and with the addition of race, body mass index and blood pressure between
(C) first and early second trimester for pre-eclampsia, (D) first and late second trimester for
pre-eclampsia, (E) first and early second trimester for early-onset pre-eclampsia or (F) first
and early second trimester for severe pre-eclampsia.
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Gestational age at sample collection (weeks)
Enrolment (first-trimester) 11.4 (10.4–12.3) 11.6 (10.6–12.3) 0.62
15–18 weeks of gestation 16.6 (16.0–17.4) 16.4 (16.0–17.0) 0.06
23–26 weeks of gestation 24.7 (24.0–25.7) 24.7 ( 24.0–25.6) 0.54
Maternal age (years) 22 (19–25) 22 (19–26) 0.88
Race 0.019
African American 51 (32.3) 103 (22.0)
Hispanic 49 (31.0) 145 (31.0)
Caucasian/other 58 (36.7) 220 (47.0)
Previous pregnancy (< 20 weeks) 34 (21.5) 97 (20.7) 0.83
Family history of pre-eclampsia 21 (13.3) 64 (13.7) 0.90
Smoked during pregnancy 26 (16.5) 79 (16.9) 0.90
BMI at enrolment 26.7 (22.9–31.6) 23.5 (21.4–27.6) < 0.001
Blood pressure at enrolment
Systolic (mmHg) 112 (108–120) 107 (100–115) < 0.001
Diastolic (mmHg) 68 (60–72) 64 (60–70) < 0.001
Treatment group 0.79
Vitamins C and E 83 (52.5) 240 (51.3)
Placebo 75 (47.8) 228 (48.7)
Data presented as n (%) or median (25–75th centile).
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